Eisai Presents New Eribulin Research at the 42nd San Antonio Breast Cancer Symposium

TOKYO, Dec. 25, 2019 /PRNewswire/ -- Eisai Co., Ltd. (headquartered in Tokyo, Japan; President: Haruo Naito; hereinafter referred to as "Eisai") recently announced that it would present data on its proprietary drug eribulin mesylate (a halichondrin B analog microtubule dynamics inhibitor; brand name: Halaven) at the 42nd San Antonio Breast Cancer Symposium (SABCS 2019).^®, hereinafter referred to as "eribulin") latest information. The symposium will be held from December 10 to 14, 2019, in San Antonio, Texas, USA.

At this San Antonio Breast Cancer Symposium (SABCS), Eisai will present five posters, including post-hoc analyses of two Phase III clinical studies evaluating baseline absolute lymphocyte count as a predictor of the impact of eribulin on overall survival in patients with advanced or metastatic breast cancer.

Eisai positions oncology as a key therapeutic area, aiming to discover revolutionary new drugs with the potential to cure cancer. We seek to further meet the diverse needs of cancer patients, their families, and healthcare providers, contributing to the enhancement of their well-being.

Key Poster Presentations at SABCS 2019:

Product, Poster No.

Poster Title and Scheduled Display Date (Local Time: Central Standard Time)

Eribulin
Poster Number: P2-15-13

Dynamic Research on Chemotherapy Management for Metastatic Breast Cancer

Thursday, December 12, 7:00–9:00 a.m.

Eribulin
Poster Number: P4-10-08

Absolute Lymphocyte Count (ALC) for Assessing Patients with Advanced or Metastatic Breast Cancer (MBC) Treated with Eribulin
Predictive Markers of Therapeutic Efficacy

Friday, December 13, 7:00–9:00 a.m.

Eribulin
Poster Number: P5-05-03

Eribulin Therapy Activates Type I Interferons, Promoting Gene Expression Signatures Associated with Antitumor Immunity

Friday, December 13, 5:00 PM–7:00 PM

Eribulin
Poster Number: P6-07-02

Evaluation of the Effects of Eribulin and Paclitaxel on Exosome Formation and Release in Triple-Negative Breast Cancer Cells

Saturday, December 14, 7:00–9:00 AM

Eribulin
Poster Number: OT2-09-01

A Multicenter, Randomized, Phase II Trial Evaluating Eribulin Monotherapy and Eribulin Combined with Endocrine Therapy
Efficacy in Patients with Locally Recurrent or Metastatic Breast Cancer After Progression on Endocrine Therapy (The REVERT Study)

December 12 (Thursday), 5:00 PM - 7:00 PM